NFKB1 and hepatocellular carcinoma: These findings imply that miR-26b may inhibit the doxorubicin-triggered NF-κB signaling via targeting TAK1 and TAB3, which in turn sensitizes HCC cells to the doxorubicin-induced apoptosis.